Impact of secukinumab on patient-reported outcomes in biologic-naive patients with psoriasis in a US real-world setting

References

• Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–516.
   PubMed Web of Science ®Google Scholar
• Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1: Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826–850.
   PubMed Web of Science ®Google Scholar
• Sampogna F, Gisondi P, Melchi CF, et al. Prevalence of symptoms experienced by patients with different clinical types of psoriasis. Br J Dermatol. 2004;151(3):594–599.
   PubMed Web of Science ®Google Scholar
• Globe D, Bayliss MS, Harrison DJ. The impact of itch symptoms in psoriasis: results from physician interviews and patient focus groups. Health Qual Life Outcomes. 2009;7:62.
   PubMed Web of Science ®Google Scholar
• Bickers DR, Lim HW, Margolis D, Society for Investigative Dermatology, et al. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol. 2006;55(3):490–500.
   PubMed Web of Science ®Google Scholar
• Edson-Heredia E, Zhu B, Guo J, et al. Disease burden and quality of life in psoriasis patients with and without comorbid psoriatic arthritis: results from National Psoriasis Foundation panel surveys. Cutis. 2015;95(3):173–178.
   PubMed Web of Science ®Google Scholar
• Fowler JF, Duh MS, Rovba L, et al. The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol. 2008;59(5):772–780.
   PubMed Web of Science ®Google Scholar
• Pearce DJ, Singh S, Balkrishnan R, et al. The negative impact of psoriasis on the workplace. J Dermatolog Treat. 2006;17(1):24–28.
   PubMed Web of Science ®Google Scholar
• Vanderpuye-Orgle J, Zhao Y, Lu J, et al. Evaluating the economic burden of psoriasis in the United States. J Am Acad Dermatol. 2015;72(6):961–967.e5.
   PubMed Web of Science ®Google Scholar
• Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258–269.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Foster SA, Comer BS, et al. Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization. BMC Dermatol. 2018;18(1):4.
   PubMedGoogle Scholar
• Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345–356.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338.
   PubMed Web of Science ®Google Scholar
• Strober BE, Bissonnette R, Fiorentino D, et al. Comparative effectiveness of biologic agents for the treatment ofpsoriasis in a real-world setting: results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). J Am Acad Dermatol. 2016;74(5):851–861.e4.
   PubMed Web of Science ®Google Scholar
• Bagel J, Blauvelt A, Nia J, et al. Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY). J Eur Acad Dermatol Venereol. 2021;35(1):135–142.
   PubMed Web of Science ®Google Scholar
• Reich K, Sullivan J, Arenberger P, et al. Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study. Br J Dermatol. 2021;184(3):425–436.
   PubMed Web of Science ®Google Scholar
• Thaçi D, Puig L, Reich K, et al. Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study. J Am Acad Dermatol. 2019;81(6):1405–1409.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Kubanov A, van Doorn M, et al. Sustained efficacy of secukinumab in patients with moderate-to-severe palmoplantar psoriasis: 2·5-year results from GESTURE, a randomized, double-blind, placebo-controlled trial. Br J Dermatol. 2020;182(4):889–899.
   PubMed Web of Science ®Google Scholar
• Augustin M, Jullien D, Martin A, et al. Real-world evidence of secukinumab in psoriasis treatment – a meta-analysis of 43 studies. J Eur Acad Dermatol Venereol. 2020;34(6):1174–1185.
   PubMed Web of Science ®Google Scholar
• Nguyen HT, Pham NTU, Tran TNA, et al. Secukinumab demonstrated high effectiveness in Vietnamese patients with moderate-to-severe plaque psoriasis in a real-world clinical setting: 16 week results from an observational study. Dermatol Ther (Heidelb). 2021;11(5):1613–1621.
   PubMed Web of Science ®Google Scholar
• Zeng JX, Luo Q, Wen J, et al. Real-world investigation of the efficacy and safety of secukinumab for psoriasis treatment in a Chinese population. Chin Med J (Engl). 2020;134(1):117–119.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Patil D, Levi E, et al. Real-world satisfaction with secukinumab in clearing the skin of patients with plaque psoriasis through 24 months of follow-up: results from US dermatology electronic medical records. Dermatol Ther (Heidelb). 2021;11(5):1733–1749.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Mease PJ, McInnes IB, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019;21(1):111.
   PubMed Web of Science ®Google Scholar
• Strober BE, Germino R, Guana A, et al. US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona psoriasis registry. J Dermatolog Treat. 2020;31(4):333–341.
   PubMed Web of Science ®Google Scholar
• Thaçi D, Körber A, von Kiedrowski R, et al. Secukinumab is effective in treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and safety from the PROSPECT study. J Eur Acad Dermatol Venereol. 2020;34(2):310–318.
   PubMed Web of Science ®Google Scholar
• Torres T, Balato A, Conrad C, et al. Secukinumab drug survival in patients with psoriasis: a multicenter, real-world, retrospective study. J Am Acad Dermatol. 2019;81(1):273–275.
   PubMed Web of Science ®Google Scholar
• Augustin M, Dauden E, Mrowietz U, et al. Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results. J Eur Acad Dermatol Venereol. 2021;35(2):431–440.
   PubMed Web of Science ®Google Scholar
• Strober B, Greenberg JD, Karki C, et al. Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona psoriasis registry. BMJ Open. 2019;9(4):e027535.
   PubMed Web of Science ®Google Scholar
• Strober B, Sigurgeirsson B, Popp G, et al. Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials. Int J Dermatol. 2016;55(4):401–407.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Regnier SA, Chirilov A, et al. Patient-reported outcomes are important elements of psoriasis treatment decision making: a discrete choice experiment survey of dermatologists in the United States. J Am Acad Dermatol. 2019;80(6):1650–1657.
   PubMed Web of Science ®Google Scholar
• Strober B, Karki C, Mason M, et al. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona psoriasis registry. J Am Acad Dermatol. 2018;78(2):323–332.
   PubMed Web of Science ®Google Scholar
• van Lumig PP, van de Kerkhof PC, Boezeman JB, et al. Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naive vs. non-naive patients. J Eur Acad Dermatol Venereol. 2013;27(5):593–600.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, Talamonti M, De Simone C, et al. Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation. Expert Opin Biol Ther. 2018;18(7):727–735.
   PubMed Web of Science ®Google Scholar
• Seneschal J, Lacour JP, Bewley A, et al. A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL). J Eur Acad Dermatol Venereol. 2020;34(11):2566–2573.
   PubMed Web of Science ®Google Scholar